Figure 2. Overall survival after IREC therapy in patients with
relapsed/refractory neuroblastoma
Overall survival (OS) was calculated from the beginning of first IREC
therapy to death from any cause. The median duration of follow-up for OS
was 9.7 months (range: 0.9–58.3). (A) OS for all patients; (B) OS
according to the disease status at the beginning of first IREC therapy;
(C) OS according to the UGT1A1 genotype.
IREC, irinotecan, etoposide, and
carboplatin.